Latest News- Cardiovascular Therapeutics Market: Hospital pharmacy is expected to lead the Distribution Channel segment during 2025-2029

The Cardiovascular Therapeutics Market is being driven by Increasing risk factors for cardiovascular diseases

The Cardiovascular Therapeutics Market is expected to grow at a CAGR of 4.6% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 25.32 billion. In the cardiovascular therapeutics market, Novel Oral Anticoagulants (NOACs) are increasingly preferred over traditional anticoagulants like heparin and warfarin. NOACs offer several advantages for patients with cardiovascular diseases, enabling easier adherence to anticoagulant therapy post-discharge. Notable NOACs include Pradaxa from Boehringer Ingelheim, Eliquis from Bristol-Myers Squibb, and Xarelto from Janssen Pharmaceuticals. NOACs boast superior pharmacological properties compared to conventional anticoagulants. Their rapid onset and offset of action, fewer drug interactions, and predictable pharmacokinetics distinguish them from traditional anticoagulants, making them a more convenient and effective treatment option for patients. 

Get more information on Cardiovascular Therapeutics Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Distribution Channel
  • Hospital pharmacy
  • Retail Pharmacy
  • Online pharmacy
• Type
  • Antithrombotic drugs
  • Hypolipidemic drugs
  • Others
• Route Of Administration
  • Oral
  • Injectable
  • Transdermal
• Geography
  • Asia
    • China
    • India
    • Japan
    • South Korea
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
    • France
    • Italy
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Increasing risk factors for cardiovascular diseases
• Availability of advanced diagnostic methods
• Rising prevalence of hypercholesterolemia

However, the market also witnesses some limitations, which are as follows:

• Advent of wearable defibrillators
• Side effects associated with cardiovascular therapeutics
• Product recalls

Benefits of Buying Global Cardiovascular Therapeutics Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in Cardiovascular Therapeutics Market Research Report

Request Free Sample

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The Cardiovascular Therapeutics market encompasses the development and production of drugs and medical technologies for treating various Cardiovascular Diseases (CVD), including coronary heart disease and myocardial infarction. Unhealthy eating habits are a leading cause of CVD, making preventive healthcare essential. Clinical trials are ongoing for beta blockers, antihypertensive drugs, hypolipidemic drugs, and antithrombotic drugs to manage blood pressure levels and prevent blood vessel damage. Cardiovascular Therapeutics research continues to advance, focusing on improving patient outcomes and reducing the global burden of this disease.

Market Research Overview

The cardiovascular therapeutics segment within the global pharmaceuticals market encompasses companies involved in the research and development (R&D) or production of various treatments for cardiovascular diseases (CVD), including coronary heart disease. According to Technavio, the global pharmaceuticals market's size is determined by the consolidated revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. The market's expansion will be fueled by several factors, including the increasing elderly population. By 2050, approximately one-quarter of the US population and Europe's population ratio is projected to be over 60 years old. Unhealthy eating habits further exacerbate the prevalence of cardiovascular diseases, necessitating the development and production of advanced therapeutics.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/